Repair biology — not SPF — defines the next decade of human resilience. A patented small-molecule platform that reactivates the body's primary DNA repair pathway: CUL4A · NER.
Sunscreen and barrier care have protected the surface of the skin for fifty years. But environmental exposure has changed faster than topical protection can compensate — and the genomic damage that drives aging, inflammation, and disease accumulates underneath.
Our patented small molecules keep the skin's master DNA repair engine — the CUL4A-mediated NER pathway — running long after it would normally shut down. Protection becomes repair. Repair becomes resilience.
Built on Cornell-origin science. Our composition-of-matter intellectual property is exclusively licensed from Cornell University.
The first topical products launch in 2027 — generating high-margin revenue from day one, proving the science in market, and funding everything that follows.
Ingestible and inhalable repair extend the platform from skin to whole-body resilience — one mechanism, every interface.
Exclusively licensed from Cornell University — developed by the scientists who discovered the target.
SPF stopped the burn — not the biology.
The visible signal is gone. The DNA damage continues.
The body's Nucleotide Excision Repair pathway is broad-spectrum — clearing damage from UV, pollution, oxidative stress, and chemical mutagens.
Under modern environmental load, the NER repair cycle shuts down within hours — long before the damage is cleared.
Over years and decades, unrepaired lesions accumulate into a backlog of genomic injury — driving premature aging, inflammation, immune dysregulation, and elevated skin-cancer risk.
For fifty years, skin science perfected the filter.
The damage outran it.
Now — with mechanism-defined DNA repair and Cornell-grade chemistry — repair becomes scalable for the first time.
Most cosmetic actives are crude extracts — botanicals, vague peptide blends, mechanisms assumed but unknown. CULGenesis is defined down to a single regulatory protein — the foundation for defensible claims, fortified IP, and platform extension into ingestible and inhalable repair.
Patented small molecules bind CUL4A and disarm the premature off-switch — extending the body's natural repair window from 6–8 hours to 24–48 hours.
CULGenesis molecules act on CUL4A — the regulatory protein that controls how long the body's DNA repair pathway stays active after exposure.
Our actives let the cell's own repair machinery run its full natural course — 24–48 hours instead of the 6–8 hours typical under modern load.
▲ Technical · CULGenesis preserves the NER scaffold (DDB2, XPC, CSA/B) from premature CUL4A-mediated degradation.
The mechanism sits at the convergence of ubiquitin-mediated regulation (2004) and nucleotide excision repair (2015) — published in peer-reviewed literature.
Topical SKUs launch in 2027 under MoCRA's cosmetic-first pathway, with platform expansion into ingestible and respiratory repair on the multi-year roadmap.
Cellular safety validated across primary keratinocyte and fibroblast models.
Not mutagenic — confirmed by standard genotoxicity panel.
Safe under direct UV exposure — necessary baseline for topical use.
Pilot human studies: accelerated DNA lesion clearance & reduced post-UV redness.
SPF blocks the burn. Senolytics clear cells after they form. NAD+ boosters rescue energy after it declines. CULGenesis sits one causal step earlier — preserving genomic integrity before damage propagates into senescence induction, mitochondrial dysfunction, or photoaging. The upstream complement to everything else.
Unrepaired DNA lesions from UV, pollution, oxidative stress, and chemical mutagens accumulate in the cell — the substrate every downstream pathology builds on.
Intervention · DNA Repair ModulationDamaged cells exit the cycle, persist in tissue, and secrete inflammatory SASP signals that propagate dysfunction to neighbors.
Intervention · SenolyticsEnergy production declines, ROS rises, repair capacity drops further — accelerating the cycle of accumulating damage in surviving cells.
Intervention · NAD+ / EnergeticsWrinkles, hyperpigmentation, barrier loss, photoaging, elevated skin-cancer risk — what's seen in the mirror is the end of the cascade.
Intervention · Topical Actives · SPFBroad-spectrum DNA repair — clearing UV photoproducts, oxidative lesions, and chemical adducts across every cell, every day.
The ubiquitin ligase that decides when NER shuts off. The master off-switch — and the target CULGenesis disarms.
Patented small molecules bind CUL4A and preserve the NER scaffold (DDB2, XPC, CSA/B) from premature degradation — keeping the body's repair engine running its full natural course.
First-in-human pilot data: faster DNA lesion clearance and significant reduction in post-UV redness vs control.
Exclusively licensed from Cornell University — developed by the scientists who originally discovered the target.
The mechanism is published in peer-reviewed journals — the foundation for defensible product claims and a credible regulatory pathway under MoCRA.
Environmental damage enters the body through three interfaces — skin, lungs, gut. CULGenesis is the first platform engineered to repair across all three. Where most interventions address a fraction of one, we close the entire loop.
A founding team uniting Cornell-origin molecular biology with operator-led commercialization.
Leading the molecular biology program that originated at Cornell. Author of the foundational peer-reviewed work behind the platform.
Building the commercial architecture that brings the platform from pilot to topical SKU and beyond — into ingestible and inhalable repair.
Bridging the mechanism to MoCRA-route product development and the peer-reviewed claims pipeline that defines our category.
◆ Full bios & advisors disclosed on request
Series A open. A high-margin topical launch in 2027 opens the first commercial revenue line. The platform extends from there into systemic and respiratory repair — closed-loop coverage across every interface.
Request our deck, IP summary, pilot data overview, and commercialization plan. Conversations welcome with strategic partners and category-defining capital.
Request Materials →Pre-empted, not deflected. Detailed answers in the deck — these are the lines.
CUL4A modulation of NER works the same way in every organ system — skin, gut, lungs. One mechanism, three interfaces, multiple SKU generations. The same patented chemistry extends across the full body, each format mechanism-locked under the same IP estate. That's the definition of a platform.
Topical SKUs launch under MoCRA — the established cosmetic-first route, no IND required, peer-reviewed mechanism supports the claims pipeline. Ingestible expansion follows the supplement/functional-ingredient pathway. Inhalable follows established inhaled-therapeutic frameworks. We're not asking regulators to invent a new category for us.
Three layers. (1) The Cornell composition-of-matter patent covers the lead molecule. (2) Mechanism patents on CUL4A binders catch competitors designing different molecules against the same target. (3) Mechanism-defined chemistry enables in-silico discovery of next-generation compounds — a pipeline competitors using crude extracts structurally cannot reproduce.
Subsequent SKUs extend into systemic and inhalable repair — same mechanism, different formulation, mechanism-protected IP. Each one compounds the moat instead of replacing it. The launch generates revenue and brand recognition while the next-generation pipeline matures behind it.
Most operate downstream of damage — senolytics clear senescent cells after they form; NAD+ boosters rescue energy after decline. CULGenesis is the only commercial platform engineered upstream, at the genomic-damage event itself. Same Hallmarks-of-Aging map. Very different intervention point. Detailed cascade comparison in Section 04.
▲ Deeper diligence answered in the deck — request below.
Investors, strategic partners, scientific collaborators, and brands building toward the next era — we welcome the conversation.
admin@CULGenesis.com